Targeting Inflammatory Cytokines in Autoimmune Diseases: Mechanisms and Therapeutic Advances with Antibody-Based Therapies
Open Access
- 19 September 2025
- journal article
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (4)
Abstract
Autoimmune diseases occur due to dysregulated immune responses against self-antigens, marked by chronic inflammation caused by pathogenic cytokine networks. Key inflammatory mediators, such as TNF-α, IL-6, IL-17, IL-23, and type I/II interferons, promote disease progression by activating autoreactive lymphocytes, recruiting immune cells, and causing ongoing tissue damage. The development of therapeutic antibodies targeting these cytokines has transformed treatment approaches, providing targeted immunomodulation while reducing systemic immunosuppression. Clinically approved biologics, including TNF inhibitors (Adalimumab, Infliximab), IL-6R blockers (Tocilizumab), and IL-17/IL-23 pathway antagonists (Secukinumab, Ustekinumab), show strong efficacy in various autoimmune conditions like rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Emerging strategies, such as bispecific antibodies and AI-optimized designs, further enhance therapeutic precision by targeting multiple inflammatory pathways or refining antibody functions simultaneously. This review highlights the pivotal role of inflammatory cytokines in autoimmune pathogenesis and assesses the clinical impact of cytokine-targeted biologics, emphasizing their potential for achieving disease modification and long-term remission. Future advancements in personalized immunomodulation are expected to improve therapeutic outcomes for refractory autoimmune diseases.Keywords
This publication has 230 references indexed in Scilit:
- Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled TrialArthritis & Rheumatology, 2025
- Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa TrialArthritis & Rheumatology, 2023
- Machine Learning for the Identification of a Common Signature for Anti–SSA/Ro 60 Antibody Expression Across Autoimmune DiseasesArthritis & Rheumatology, 2022
- Tocilizumab for giant cell arteritisCochrane Database of Systematic Reviews, 2022
- Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyArthritis & Rheumatology, 2021
- Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid ArthritisArthritis & Rheumatology, 2021
- Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2020
- Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3CL1/CX3CR1 Pathway in Experimental Mouse Models of Systemic SclerosisArthritis & Rheumatology, 2019
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyArthritis & Rheumatology, 2015
- Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory ReceptorArthritis & Rheumatology, 2013